CureVac NV (WBO:CVAC) Total Assets : €842.57 Mil (As of Sep. 2023)

View and export this data going back to 2020. Start your Free Trial

What is CureVac NV Total Assets?

CureVac NV's Total Assets for the quarter that ended in Sep. 2023 was €842.57 Mil.

During the past 12 months, CureVac NV's average Total Assets Growth Rate was 10.10% per year. During the past 3 years, the average Total Assets Growth Rate was 51.60% per year.

During the past 5 years, CureVac NV's highest 3-Year average Total Assets Growth Rate was 73.50%. The lowest was 51.60%. And the median was 62.55%.

Total Assets is connected with ROA %. CureVac NV's annualized ROA % for the quarter that ended in Sep. 2023 was -22.36%. Total Assets is also linked to Revenue through Asset Turnover. CureVac NV's Asset Turnover for the quarter that ended in Sep. 2023 was 0.02.

CureVac NV Total Assets Historical Data

The historical data trend for CureVac NV's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CureVac NV Total Assets Chart

CureVac NV Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Total Assets

125.66

130.62

1,511.36

1,158.24

860.47

CureVac NV Quarterly Data
	Dec18	Mar19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Total Assets	Get a 7-Day Free Trial														910.51	860.47	973.67	899.48	842.57

CureVac NV Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

CureVac NV's Total Assets for the fiscal year that ended in Dec. 2022 is calculated as

Total Assets	=	Total Equity (A: Dec. 2022 )	+	Total Liabilities (A: Dec. 2022 )
	=	533.253	+	327.219
	=	860.47

CureVac NV's Total Assets for the quarter that ended in Sep. 2023 is calculated as

Total Assets	=	Total Equity (Q: Sep. 2023 )	+	Total Liabilities (Q: Sep. 2023 )
	=	602.265	+	240.301
	=	842.57

CureVac NV (WBO:CVAC) Total Assets Explanation

Total Assets is connected with ROA %.

CureVac NV's annualized ROA % for the quarter that ended in Sep. 2023 is

ROA %	=	Net Income (Q: Sep. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Sep. 2023 ))	/ count )
	=	-194.724	/	( (899.48	+	842.566)	/ 2 )
	=	-194.724	/	871.023
	=	-22.36 %

Note: The Net Income data used here is four times the quarterly (Sep. 2023) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

CureVac NV's Asset Turnover for the quarter that ended in Sep. 2023 is

	Asset Turnover
=	Revenue (Q: Sep. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Sep. 2023 ))	/ count )
=	16.483	/	( (899.48	+	842.566)	/ 2 )
=	16.483	/	871.023
=	0.02

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

CureVac NV Total Assets Related Terms

Thank you for viewing the detailed overview of CureVac NV's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

CureVac NV (WBO:CVAC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CureVac NV (WBO:CVAC) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

CVAC:USA CVAC:Mexico 1CVAC:Italy 0A9E:UK 5CV:Germany

Address

Friedrich-Miescher-Strasse 15, Tubingen, BW, DEU, 72076

Website

https://www.curevac.com

CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.